Zhenxin Anshen formula(镇心安神方)ameliorates atopic der-matitis-like skin dysfunction in mice and in vitro via regulation of transient receptor potential vanilloid 1 and transient receptor potential ankyrin 1 in Neural pathways  

作　　者：ZHAO Yiding YAN Xiaoning JIANG Shanshan LIU Yong DONG Chun CHI Huiyan MAO Chaoyi 

机构地区：[1]Department of Dermatology,Shaanxi Provincial Hospital of traditional Chinese Medicine,Xi’an 710003,China [2]Department of Dermatology,Xiyuan Hospital China Academy of Chinese Medical Sciences,Beijing 100193,China [3]Department of Education Management,China Academy of Chinese Medical Sciences,Beijing 100700,China

出　　处：《Journal of Traditional Chinese Medicine》2023年第5期887-896,共10页中医杂志（英文版）

基　　金：the National Natural Science Foundation of China:Study on the Mechanism of Zhenxin Anshen Formula Regulating GRPR/MrgprA3/TRPs Signaling Pathway for Atop-ic Dermatitis based on the Theory of All Kinds of Diseases with Pain;Itching;and Sores are Exclusively Related to the Heart;No.81704087;the Regulation of Zhenxin Anshen Formula on Neuroimmune Function in Atopic Dermatitis from STIM1-ORAI1 Mediated Store Oper-ated Calcium Entry;No.82274537;Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences:Based on PAR2/TRPV1 Pathway to Regulate Nerve-Epidermal Pruritus Information Transmission to Explore the Mechanism of Longmu Decoction on“Stress-Type Atopic Dermatitis”Mice;No.CI2021A02315;Belt and Road Initiative Cooperation Project of Traditional Chinese Medicine of the Chinese Academy of Traditional Chinese Medicine:Evaluation of the Effect of Chinese Medicine on Allergic Diseases and Material Basis Research;No.GH201910。

摘　　要：OBJECTIVE:To investigate the efficacy of Zhenxin Anshen formula(镇心安神方,ZXAS)on atopic dermatitis(AD)by transient receptor potential vanilloid 1(TRPV1)and transient receptor potential ankyrin 1(TRPA1)signalling pathway in mice and in vitro.METHODS:AD-like lesions were induced by 1-chloro-2,4-dinitrobenzene(DNCB)to the shaved dorsal skin of BALB/c mice.BALB/c mice were divided into five groups:normal control,model control,cetirizine,low-,medium-,and high-dose of ZXAS.After ZXAS in-tervention,the skin lesions and blood samples were collected for hematoxylin and eosin-stained and measuring the concentrations of inflammatory cytokines.Immunoglobulin E(IgE),interleukin(IL)-4,IL-5,IL-13,and thymic stromal lymphopoietin(TSLP)were de-tected by Enzyme-linked immunosorbent assay(ELISA).The spinal cords were collected for measuring the expression of gastrin-releasing peptide receptor(GRPR),TRPV1,and TRPA1 by using immunohistochemistry,western blotting,and quantitative real-time polymerase chain reaction(qR T-PCR)analyses.In addition,3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide(MTT)assay,flow cytometry,ELISA,and Western blotting were conducted for analysis of primary dorsal root ganglia(DRG)neurons in vitro.RESULTS:ZXAS treatment improved DNCB-induced AD-like lesions through reducing dermatitis score,number of scratching and epidermal thickness,accompanied by the de-creased IgE and Th2 inflammatory cytokines.ZXAS also supressed the mRNA and protein expression of GRPR,TRPV1,and TRPA1 in the spinal cord.The medicated sera of ZXAS decreased capsaicin-induced Ca^(2+)influx and downregulated the expression of TRPV1,TRPA1,and phospholipase C in DRG neurons.CONCLUSIONS:The therapeutic effect of ZXAS on AD may be related to the regulation of TRPV1 and TRPA1 and inhibition of Ca^(2+)signals in neurons.

关 键 词：DERMATITIS ATOPIC PRURITUS neural pathways transient receptor potential vanil-loid 1 transient receptor potential ankyrin 1 Zhenxin Anshen formula 

分 类 号：R285.5[医药卫生—中药学]